Recurrence Cancer

One of the greatest fears of lymphoma survivors is that they’ll relapse and have to undergo treatment again. This fear is normal but awful to deal with. Chemotherapy, radiation, and other treatments are difficult to handle the first time around, so no patient wants to repeat that experience.

Handling this fear is necessary for lymphoma patients to heal mentally. Talk to your friends and family about your feelings, and talk to a therapist if necessary (if you are experiencing extreme anxiety).

These fears usually diminish over time as you regain your health, so be patient. Remember that lymphomas are usually very treatable, and your chances of survival are great. Talk to your doctor if your anxiety makes you physically sick (nauseous). Anti-anxiety medication may be needed in some cases, but it’s likely the doctor will tell you to practice relaxation techniques.

Meditation, yoga, and other exercise can help patients concur fears. Do not be afraid to try different things. Other helpful items include acupuncture, chiropractic care, art therapy and music therapy. Having a great support system in your friends and family is the other important factor in beating your fears, and thus beating cancer for good.

Dive Deeper

Resources

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap